Prochain catalyseur en 2016 : Graspa dans la LAL - ACHAT - OC 39€ (vs 41€)
Suite à la publication des résultats annuels, la société a organisé une conférence téléphonique afin d’étayer sa stratégie court et moyen terme ainsi que ses plans de développement. Bien que peu d’annonces tangibles ont été faites, la présentation s’est révélée rassurante et en ligne avec les objectifs initialement transmis par la société au marché. Nous pensons que l’année 2016 sera principalement dirigée par la potentielle approbation de Graspa dans la LAL en Europe ainsi que par les premiers résultats d’ERYASP dans le traitement du cancer du pancréas. L’évolution du pipeline de la société nous conduit à augmenter nos frais de R&D et de structure à court terme. Par conséquent, nous ajustons notre un objectif de cours de 41€ à 39€/action et maintenons notre recommandation à ACHAT.Erytech Pharma is a pharmaceutical company based in France. Co. is primarily engaged in developing cancer therapies that work by starving tumors. Co.'s first product (ERY-ASP), which is in phase III development, provides a therapeutic solution to frail patients with acute leukemia. Co.'s proprietary technology is based on encapsulation of therapeutic molecules into red blood cells. Co. maintains a production unit located in Lyons with "Pharmaceutical Establishment" status. Co. has also signed two distribution partnership agreements with the Orphan Europe-Recordati company and the TEVA group.
Since 2006, Invest Securities has become one of the leading players in investment services for funds and managers, to whom we offer a global and personalised service. Our track record differentiates us and proves our leadership in numerous promising sectors like property and growth companies.
Consisting of 13 different profiles (pharmacist, engineer, financier, etc), the DNA of our financial analysis office is value added and sector expertise. Through daily monitoring and detailed analyses of companies and sectors, we seek to provide a differentiating vision of our 120 stocks followed. Our ideas are circulated every day to nearly 1,000 professionals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.